This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Alvarez, J. V. Articles by Frank, D. A. Search for Related Content PubMed PubMed Citation Articles by Alvarez, J. V. Articles by Frank, D. A.

Signal Transducer and Activator of Transcription 3 Is Required for the Oncogenic Effects of Non–Small-Cell Lung Cancer–Associated Mutations of the Epidermal Growth Factor Receptor

¹ Department of Medical Oncology, Dana-Farber Cancer Institute; ² Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; ³ Department of Pathology, Harvard Medical School, Boston, Massachusetts; and ⁴ The Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts

Requests for reprints: David A. Frank, Department of Medical Oncology, Mayer 522B, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115. Phone: 617-632-4714; Fax: 617-632-6356; E-mail: david_frank{at}dfci.harvard.edu.

Somatic mutations in the epidermal growth factor receptor (EGFR) occur frequently in lung cancer and confer sensitivity to EGFR kinase inhibitors gefitinib and erlotinib. These mutations, which occur in the kinase domain of the protein, also render EGFR constitutively active and transforming. Signal transducers and activators of transcription 3 (STAT3) transduces signals from a number of oncogenic tyrosine kinases and contributes to a wide spectrum of human malignancies. Here, we show that STAT3 is activated by mutant EGFRs and is necessary for its downstream phenotypic effects. Inhibiting STAT3 function in fibroblasts abrogates transformation by mutant EGFR. In non–small-cell lung cancer cells, STAT3 activity is regulated by EGFR through modulation of STAT3 serine phosphorylation. Inhibiting STAT3 function increases apoptosis of these cells, suggesting that STAT3 is necessary for their survival. Finally, a group of genes constituting a STAT3 signature is enriched in lung tumors with EGFR mutations. Thus, STAT3 is a critical mediator of the oncogenic effects of somatic EGFR mutations and targeting STAT3 may be an effective strategy for treating tumors characterized by these mutations. (Cancer Res 2006; 66(6): 3162-8)

This article has been cited by other articles:

				J. M. Brannan, W. Dong, L. Prudkin, C. Behrens, R. Lotan, B. N. Bekele, I. Wistuba, and F. M. Johnson Expression of the Receptor Tyrosine Kinase EphA2 Is Increased in Smokers and Predicts Poor Survival in Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2009; 15(13): 4423 - 4430. [Abstract] [Full Text] [PDF]

				J. SHEN, R. LI, and G. LI Inhibitory Effects of Decoy-ODN Targeting Activated STAT3 on Human Glioma Growth In Vivo In Vivo, March 1, 2009; 23(2): 237 - 243. [Abstract] [Full Text] [PDF]

				M. M. Schittenhelm, C. Kollmannsberger, K. Oechsle, A. Harlow, J. Morich, F. Honecker, R. Kurek, S. Storkel, L. Kanz, C. L. Corless, et al. Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer Mol. Cancer Ther., March 1, 2009; 8(3): 481 - 489. [Abstract] [Full Text] [PDF]

				E. A. Nelson, S. R. Walker, A. Kepich, L. B. Gashin, T. Hideshima, H. Ikeda, D. Chauhan, K. C. Anderson, and D. A. Frank Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3 Blood, December 15, 2008; 112(13): 5095 - 5102. [Abstract] [Full Text] [PDF]

				L.-Y. Kong, M. K. Abou-Ghazal, J. Wei, A. Chakraborty, W. Sun, W. Qiao, G. N. Fuller, I. Fokt, E. A. Grimm, R. J. Schmittling, et al. A Novel Inhibitor of Signal Transducers And Activators Of Transcription 3 Activation Is Efficacious Against Established Central Nervous System Melanoma and Inhibits Regulatory T Cells Clin. Cancer Res., September 15, 2008; 14(18): 5759 - 5768. [Abstract] [Full Text] [PDF]

				K. Kataoka, D. J. Kim, S. Carbajal, J. L. Clifford, and J. DiGiovanni Stage-specific disruption of Stat3 demonstrates a direct requirement during both the initiation and promotion stages of mouse skin tumorigenesis Carcinogenesis, June 1, 2008; 29(6): 1108 - 1114. [Abstract] [Full Text] [PDF]

				J. A. Engelman and P. A. Janne Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Clin. Cancer Res., May 15, 2008; 14(10): 2895 - 2899. [Abstract] [Full Text] [PDF]

				R. Ahmad, D. Raina, C. Meyer, and D. Kufe Triterpenoid CDDO-Methyl Ester Inhibits the Janus-Activated Kinase-1 (JAK1)->Signal Transducer and Activator of Transcription-3 (STAT3) Pathway by Direct Inhibition of JAK1 and STAT3 Cancer Res., April 15, 2008; 68(8): 2920 - 2926. [Abstract] [Full Text] [PDF]

				D. A Frank Targeting Transcription Factors for Cancer Therapy Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 335 - 341. [Abstract] [Full Text] [PDF]

				H.-P. Kim, S.-W. Han, S.-H. Kim, S.-A. Im, D.-Y. Oh, Y.-J. Bang, and T.-Y. Kim Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells Mol. Cancer Ther., March 1, 2008; 7(3): 607 - 615. [Abstract] [Full Text] [PDF]

				D. Germain and D. A. Frank Targeting the Cytoplasmic and Nuclear Functions of Signal Transducers and Activators of Transcription 3 for Cancer Therapy Clin. Cancer Res., October 1, 2007; 13(19): 5665 - 5669. [Abstract] [Full Text] [PDF]

				A. Edwards, J. Li, P. Atadja, K. Bhalla, and E. B. Haura Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor dependent human lung cancer cells Mol. Cancer Ther., September 1, 2007; 6(9): 2515 - 2524. [Abstract] [Full Text] [PDF]

				S. C. Kiley and R. L. Chevalier Species differences in renal Src activity direct EGF receptor regulation in life or death response to EGF Am J Physiol Renal Physiol, September 1, 2007; 293(3): F895 - F903. [Abstract] [Full Text] [PDF]

				F. M. Johnson, B. Saigal, H. Tran, and N. J. Donato Abrogation of Signal Transducer and Activator of Transcription 3 Reactivation after Src Kinase Inhibition Results in Synergistic Antitumor Effects Clin. Cancer Res., July 15, 2007; 13(14): 4233 - 4244. [Abstract] [Full Text] [PDF]

				T. de La Motte Rouge, L. Galluzzi, K. A. Olaussen, Y. Zermati, E. Tasdemir, T. Robert, H. Ripoche, V. Lazar, P. Dessen, F. Harper, et al. A Novel Epidermal Growth Factor Receptor Inhibitor Promotes Apoptosis in Non-Small Cell Lung Cancer Cells Resistant to Erlotinib Cancer Res., July 1, 2007; 67(13): 6253 - 6262. [Abstract] [Full Text] [PDF]

				R. A. Lynch, J. Etchin, T. E. Battle, and D. A. Frank A Small-Molecule Enhancer of Signal Transducer and Activator of Transcription 1 Transcriptional Activity Accentuates the Antiproliferative Effects of IFN-{gamma} in Human Cancer Cells Cancer Res., February 1, 2007; 67(3): 1254 - 1261. [Abstract] [Full Text] [PDF]

				G. J. Riely, K. A. Politi, V. A. Miller, and W. Pao Update on Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer Clin. Cancer Res., December 15, 2006; 12(24): 7232 - 7241. [Abstract] [Full Text] [PDF]

				J Riedemann and V M Macaulay IGF1R signalling and its inhibition Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S33 - S43. [Abstract] [Full Text] [PDF]